Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Sitagliptin 100 mg tablets vs Januvia 100 mg tablets in healthy Thai volunteers under fasting
TCTR20210406003Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Bio-innova. Primary endpoint: Bioequivalence of pharmacokinetic parameters. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20210406003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210406003.